RICHMOND, Calif., Nov. 8 Sangamo BioSciences,Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's presidentand CEO, will provide an update on the progress of Sangamo's ZFP Therapeuticdevelopment programs and an overview of the company's business strategy at12:30 pm (ET) on Tuesday, November 13, 2007 at the JMP Securities HealthcareConference in Boston.
The presentation will be webcast live and may be accessed via a link onthe Sangamo BioSciences website in the Investor Relations sectionhttp://investor.sangamo.com/index.cfm under Events and Presentations. Thepresentation will be archived on the Sangamo website for two weeks after theevent.
Sangamo BioSciences, Inc. is focused on the research and development ofnovel DNA-binding proteins for therapeutic gene regulation and modification.The most advanced ZFP Therapeutic(TM) development program is currently inPhase 2 clinical trials for evaluation of safety and clinical effect inpatients with diabetic neuropathy. Phase 1 clinical trials are ongoing toevaluate a ZFP Therapeutic for peripheral artery disease. Other therapeuticdevelopment programs are focused on cancer and HIV/AIDS, neuropathic pain,nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo'score competencies enable the engineering of a class of DNA-binding proteinsknown as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs thatrecognize a specific DNA sequence Sangamo has created ZFP transcriptionfactors (ZFP TF(TM)) that can control gene expression and, consequently, cellfunction. Sangamo is also developing sequence-specific ZFP Nucleases(ZFN(TM)) for gene modification. Sangamo has established strategicpartnerships with companies outside of the human therapeutic space includingDow AgroSciences, Sigma-Aldrich and several companies applying its ZFPTechnology to enhance the production of protein pharmaceuticals. For moreinformation about Sangamo, visit the company's web site athttp://www.sangamo.com.
This press release may contain forward-looking statements based onSangamo's current expectations. These forward-looking statements include,without limitation, references to the research and development of novel ZFPTFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technologyplatform, strategic partnerships with collaborators and clinical trials of ZFPTherapeutics. Actual results may differ materially from these forward-lookingstatements due to a number of factors, including technological challenges,uncertainties relating to the initiation and completion of stages of ZFPTherapeutic clinical trials, Sangamo's ability to develop commercially viableproducts and technological developments by our competitors. See the company'sSEC filings, and in particular, the risk factors described in the company'sAnnual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences,Inc. assumes no obligation to update the forward-looking information containedin this press release.
SOURCE Sangamo BioSciences, Inc.